Key result
TNNT2-4Fpolycistronic-NIL gene therapy reduces scar size and improves LV function in ischemic heart failure rats.
Why the study?
Gene therapies inducing cardiomyocyte cell cycle re-entry showed potential in subacute ischaemic heart failure but had not been tested in chronic ischaemic heart failure.
Does TNNT2-4Fpolycistronic-NIL gene therapy improve LV function and reduce scar size in a rat model of chronic ischemic heart failure?
Does TNNT2-4Fpolycistronic-NIL gene therapy improve LV function and reduce scar size in a rat model of chronic ischemic heart failure?
TNNT2-4Fpolycistronic-NIL gene therapy induces cardiomyocyte cell cycle re-entry, reduces scar size, and improves LV systolic function in a rat model of chronic ischemic heart failure.
Answers are grounded in this paper and cite their sources.
Does not inform clinical practice; leaves open translation of TNNT2-4Fpolycistronic-NIL gene therapy to human chronic ischemic HF.
AIMS: Gene therapies to induce cardiomyocyte (CM) cell cycle re-entry have shown a potential to treat subacute ischaemic heart failure (IHF) but have not been tested in the more relevant setting of chronic IHF. Our group recently showed that polycistronic non-integrating lentivirus encoding Cdk1/CyclinB1 and Cdk4/CyclinD1 (TNNT2-4Fpolycistronic-NIL) is effective in inducing CM cell cycle re-entry and ameliorating subacute IHF models and preventing the subsequent IHF-induced congestions in the liver, kidneys, and lungs in rats and pigs. Here, we aim to test the long-term efficacy of TNNT2-4Fpolycistronic-NIL in a rat model of chronic IHF, a setting that differs pathophysiologically from subacute IHF and has greater clinical relevance. METHODS AND RESULTS: Rats were subjected to a 2-h coronary occlusion followed by reperfusion; 4 weeks later, rats were injected intramyocardially with either TNNT2-4Fpolycistronic-NIL or LacZ-NIL. Four months post-viral injection, TNNT2-4Fpolycistronic-NIL-treated rats showed a significant reduction in scar size and a significant improvement in left ventricular (LV) systolic cardiac function but not in the LV dilatation associated with chronic IHF. A mitosis reporter system developed in our lab showed significant induction of CM mitotic activity in TNNT2-4Fpolycistronic-NIL-treated rats. CONCLUSION: This study demonstrates, for the first time, that TNNT2-4Fpolycistronic-NIL gene therapy induces CM cell cycle re-entry in chronic IHF and improves LV function, and that this salubrious effect is sustained for at least 4 months. Given the high prevalence of chronic IHF, these results have significant clinical implications for developing a novel treatment for this deadly disease.
No takes yet. Share an insight, caveat, or question.
Abouleisa et al. (2024) studied chronic ischemic heart failure. TNNT2-4Fpolycistronic-NIL vs. LacZ-NIL was evaluated on scar size and left ventricular (LV) systolic cardiac function. TNNT2-4Fpolycistronic-NIL gene therapy significantly reduced scar size and improved left ventricular systolic cardiac function at 4 months in rats with chronic ischemic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: